½ÃÀ庸°í¼­
»óǰÄÚµå
1618226

°üÀýÅë ÁÖ»ç ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)

Joint Pain Injections Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°üÀýÅëÁõ ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2023³â 36¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â°£ ¿¬Æò±Õ 7.7% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡¿Í Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÁÖ»çÁ¦ À¯Çü¿¡ µû¶ó È÷¾Ë·ç·Ð»ê ÁÖ»ç, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÁÖ»ç, ´ÙÇ÷¼ÒÆÇ Ç÷Àå ÁÖ»ç·Î ³ª´µ¸ç, 2023³â¿¡´Â È÷¾Ë·ç·Ð»ê Áֻ簡 64.8%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 7.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ °í·ÉÈ­¿Í Çõ½ÅÀûÀÎ Á¦Ç°ÀÇ Ã¤ÅÃÀÌ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å¼ÓÇÑ ÀÓ»ó °á°ú¸¦ Á¦°øÇÏ´Â ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ È÷¾Ë·ç·Ð»ê Áֻ翡 ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. È÷¾Ë·ç·Ð»ê ÁÖ»ç´Â ÁÖ·Î ¹«¸­ °ñ°üÀý¿° Ä¡·á¿¡ »ç¿ëµÇ¸ç, °üÀý ³» ġȯ¼ú·Î ¾Ë·ÁÁø ¹æ¹ýÀ¸·Î °üÀý ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. °üÀýÅë ÁÖ»ç ½ÃÀåÀº ¹«¸­, ¾î±ú ¹× ÆÈ²ÞÄ¡, ¹ß¸ñ, °í°üÀý, ±âŸ °üÀý µî °üÀý À¯Çüº°·Îµµ ºÐ·ùµË´Ï´Ù. ¹«¸­ °üÀý ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ °°Àº ±Þ°ÝÇÑ ¼ºÀåÀº ¹«¸­ °ü·Ã Áúȯ, ƯÈ÷ ¿¬°ñ°ú »À°¡ Á¡Â÷ÀûÀ¸·Î ¾ÇÈ­µÇ´Â °ñ°üÀý¿°ÀÇ ³ôÀº À¯º´·üÀÌ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ³ë³âÃþ¿¡¼­ ÈçÇÑ ÁúȯÀÎ ¹«¸­ °ñ°üÀý¿°Àº ºÒÆíÇÔ°ú ¿îµ¿ Á¦ÇÑÀ» ÃÊ·¡ÇÕ´Ï´Ù. Ç¥ÁØ Ä¡·á¹ý¿¡´Â ¹°¸®Ä¡·á, ÀçȰġ·á, ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦, È÷¾Ë·ç·Ð»ê °üÀý ³» ġȯ¼ú µîÀÌ Æ÷ÇԵǸç, °üÀýÅë ÁÖ»ç´Â ÀÌ·¯ÇÑ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ ÀÖ¾î °üÀýÅë ÁÖ»çÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. Áö¿ªº° ºÐ¼®¿¡¼­´Â ºÏ¹Ì°¡ 2023³â 47.4%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÇâÈÄ ¸î ³âµ¿¾È Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024-2032³â
½ÃÀÛ °¡°Ý 36¾ï ´Þ·¯
¿¹»ó °¡°Ý 72¾ï ´Þ·¯
CAGR 7.7%

ÀÌ °°Àº ¿ìÀ§´Â ÁÖ·Î °üÀý¿° ¹× ±âŸ Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÷´Ü Ä¡·á ¿É¼ÇÀÇ ºü¸¥ µµÀÔ¿¡ ±âÀÎÇÕ´Ï´Ù. ½ºÆ÷Ã÷ ¹× »ç°í·Î ÀÎÇÑ ºÎ»ó Áõ°¡, °í·ÉÈ­ Àα¸ÀÇ °üÀý Áúȯ À¯º´·ü Áõ°¡, Ä¡·á ¼Ö·ç¼ÇÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Á¤Çü¿Ü°ú Áúȯ Áõ°¡
      • ±â¼ú Áøº¸
      • ½½ÅëÁÖ»ç ¼ö¿ä Áõ°¡
      • °üÀýÅë°ú ¿°ÁõÀ» ¿ÏÈ­½ÃŰ´Â Ä¡·á ¿ìÀ§¼º
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • °üÀýÅë ÁÖ»ç °íºñ¿ë
      • °üÀýÅë Áֻ翡 ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼úÀû Àü¸Á
    • Áٱ⼼Æ÷ Ä¡·á
    • Àúħ½À ½Ã¼ú
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °üÀýÅë ¿ªÇÐ ½Ã³ª¸®¿À
  • »óȯ ½Ã³ª¸®¿À
  • °¡°Ý ºÐ¼®, 2023³â
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
    • ¼¼°è
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÀÎÁ§¼Ç À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • È÷¾Ë·ç·Ð»ê ÁÖ»ç
  • ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å ÁÖ»ç
  • Ç÷¼ÒÆÇdzºÎÇ÷Àå ÁÖ»ç

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : °üÀý À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ½½°üÀý
  • °ß¡¤ÁÖ
  • Á·°üÀý¡¤°í°üÀý
  • ±âŸ °üÀý À¯Çü

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦9Àå ±â¾÷ °³¿ä

  • Anika Therapeutics, Inc.
  • Arthrex
  • Bioventus
  • Emcyte Corporation
  • Ferring B.V.
  • Lifecore Biomedical
  • OrthogenRx
  • Pacira BioSciences(Flexion)
  • Pfizer, Inc.
  • Sanofi S.A.
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
LSH 25.01.09

The Global Joint Pain Injections Market was valued at USD 3.6 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2032. The increasing elderly population and the rising incidence of orthopedic conditions drive this market's expansion. The market is divided by injection type into hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. In 2023, hyaluronic acid injections dominated the market with a 64.8% revenue share and are expected to experience a notable CAGR of 7.9% during the forecast period. The combination of an aging demographic and the introduction of innovative products is anticipated to boost market growth.

There is a growing preference for minimally invasive procedures that deliver rapid clinical outcomes, further enhancing the demand for hyaluronic acid injections. These injections are primarily used for treating knee osteoarthritis and are recognized for their ability to improve joint function through a method known as viscosupplementation. The joint pain injections market is also categorized by joint type, including knee, shoulder and elbow, ankle, and hip, as well as other joints. The knee segment is expected to experience significant growth, with projections indicating it will reach USD 2.7 billion during the analysis period.

This surge is largely driven by the high prevalence of knee-related disorders, particularly osteoarthritis, characterized by the gradual deterioration of cartilage and bone. As a common ailment among the elderly, osteoarthritis leads to discomfort and restricted mobility. Standard treatment options often include physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation with hyaluronic acid, underscoring the importance of joint pain injections in managing these conditions. In terms of regional analysis, North America held the largest market share at 47.4% in 2023, with substantial growth anticipated in the upcoming years.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$3.6 Billion
Forecast Value$7.2 Billion
CAGR7.7%

This dominance is primarily attributed to the rising incidence of arthritis and other orthopedic disorders, alongside the swift adoption of advanced treatment options. The growing prevalence of joint conditions among the aging population, in line with an increase in injuries from sports and accidents, as well as continuous innovation in therapeutic solutions, are vital factors driving market growth in this region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of orthopedic diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising demand for knee pain injections
      • 3.2.1.4 Therapeutics advantages to relieve joint pain & inflammation
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of joint pain injections
      • 3.2.2.2 Side effects associated with joint pain injections
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
    • 3.4.1 Stem cell therapy
    • 3.4.2 Minimally invasive procedures
  • 3.5 Pipeline analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Future market trends
  • 3.8 Joint pain epidemiology scenario
  • 3.9 Reimbursement scenario
  • 3.10 Pricing analysis, 2023
  • 3.11 Gap analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Injection Type, 2018 - 2032 ($ Mn and Units)

  • 5.1 Key trends
  • 5.2 Hyaluronic acid injections
  • 5.3 Corticosteroid injections
  • 5.4 Platelet rich plasma injections

Chapter 6 Market Estimates and Forecast, By Joint Type, 2018 - 2032 ($ Mn and Units)

  • 6.1 Key trends
  • 6.2 Knee
  • 6.3 Shoulder & elbow
  • 6.4 Ankle & hip
  • 6.5 Other joint types

Chapter 7 Market Estimates and Forecast, By End Use, 2018 - 2032 ($ Mn and Units)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn and Units)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Anika Therapeutics, Inc.
  • 9.2 Arthrex
  • 9.3 Bioventus
  • 9.4 Emcyte Corporation
  • 9.5 Ferring B.V.
  • 9.6 Lifecore Biomedical
  • 9.7 OrthogenRx
  • 9.8 Pacira BioSciences (Flexion)
  • 9.9 Pfizer, Inc.
  • 9.10 Sanofi S.A.
  • 9.11 Stryker Corporation
  • 9.12 Zimmer Biomet Holdings, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦